List of Excipients in Branded Drug FASLODEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	FASLODEX	fulvestrant	0310-0720	ALCOHOL
AstraZeneca Pharmaceuticals LP	FASLODEX	fulvestrant	0310-0720	BENZYL ALCOHOL
AstraZeneca Pharmaceuticals LP	FASLODEX	fulvestrant	0310-0720	BENZYL BENZOATE
AstraZeneca Pharmaceuticals LP	FASLODEX	fulvestrant	0310-0720	CASTOR OIL

Last updated: August 27, 2026

Faslodex (fulvestrant) is a ready-to-use intramuscular estrogen-receptor antagonist formulated as an oil-based injection. Its commercial opportunity has shifted from originator exclusivity to generic supply, formulation redesign, prefilled-device improvements, and excipient systems that reduce injection burden while preserving bioequivalence. The core formulation uses refined castor oil, benzyl benzoate, benzyl alcohol, and ethanol. Any material change to that vehicle can create regulatory, stability, injectability, and patent-design-around issues.

Faslodex Excipient Strategy, Patent Position, and Commercial Opportunities

What is Faslodex and how is it administered?

Faslodex is AstraZeneca’s brand of fulvestrant, a selective estrogen receptor degrader approved for hormone receptor-positive metastatic or locally advanced breast cancer. It is administered by slow intramuscular injection into the buttocks.

The current labeled regimen for most adult patients is:

Parameter	Faslodex specification
Active ingredient	Fulvestrant
Strength	250 mg/5 mL
Standard monthly dose	500 mg
Injection burden	Two 5 mL injections
Route	Intramuscular
Administration site	Gluteal muscle
Dosage form	Sterile solution in prefilled syringe
Loading schedule	500 mg on Days 1, 15, and 29, then every 28 days
Manufacturer	AstraZeneca
Primary therapeutic area	HR-positive advanced or metastatic breast cancer

Faslodex is supplied as a 250 mg/5 mL solution. The 500 mg dose requires two separate syringes, usually administered as two injections, one in each buttock. The product’s viscosity, oil vehicle, needle gauge, injection speed, and syringe design directly affect administration time and patient discomfort. [1]

What excipients are used in Faslodex?

Faslodex uses a nonaqueous, oil-based vehicle rather than an aqueous injectable system. The listed inactive ingredients are:

Excipient	Functional role	Commercial relevance
Refined castor oil	Primary vehicle and solubilizing medium	Controls drug solubility, viscosity, and depot behavior
Benzyl benzoate	Cosolvent and vehicle component	Supports solubilization of fulvestrant
Benzyl alcohol	Preservative and cosolvent	Affects tolerability, regulatory labeling, and extractables risk
Ethanol, 96%	Cosolvent	Improves solubility but contributes to volatility and local tolerability

The formulation does not use water for injection as the primary vehicle. This is important because fulvestrant has limited aqueous solubility, and the product depends on an organic/oily solvent system to maintain concentration and physical stability. [1,2]

The excipient system must maintain:

• Fulvestrant solubility during manufacture and storage
• Chemical stability of the steroidal active ingredient
• Sterility through the product shelf life
• Acceptable syringe compatibility
• Controlled viscosity for intramuscular delivery
• Limited precipitation after injection
• Acceptable local tissue tolerability
• Consistent dose delivery from a prefilled syringe

Why does Faslodex use castor oil and benzyl benzoate?

Refined castor oil provides the principal lipophilic vehicle for fulvestrant. Benzyl benzoate acts as a cosolvent and changes the solvent environment enough to support the required drug concentration. Ethanol provides additional solubilization capacity. Benzyl alcohol contributes both solvent and preservative properties.

This system is commercially effective because it avoids the need for a high-volume aqueous injection. Its disadvantage is the high viscosity and organic-solvent content associated with administration. The vehicle can increase injection resistance, prolong injection time, and complicate the development of a smaller-volume or higher-concentration product.

The excipient strategy is therefore a tradeoff:

Formulation objective	Benefit	Development constraint
High lipophilic solvent capacity	Maintains fulvestrant concentration	Can increase local irritation
Castor-oil depot	Supports prolonged drug exposure	Creates high viscosity
Prefilled syringe	Reduces preparation steps	Requires strong container-closure compatibility
Benzyl alcohol inclusion	Supports preservation and solubilization	Raises toxicological and labeling considerations
Ethanol cosolvent	Improves solubility	Can affect tolerability and package materials
Two 5 mL injections	Fits the approved strength	Creates a significant administration burden

What excipient opportunities exist for generic fulvestrant?

The largest near-term opportunity is not a wholesale replacement of the vehicle. It is optimization around the existing formulation architecture.

1. Lower-viscosity vehicle systems

A generic manufacturer could evaluate alternative ratios of castor oil, benzyl benzoate, ethanol, and benzyl alcohol to reduce injection force. The formulation must retain fulvestrant concentration, prevent crystallization, and match the reference product’s pharmacokinetic behavior.

A lower-viscosity formulation could support:

• Faster administration
• Smaller-gauge needles
• Lower injection force
• Better compatibility with autoinjector concepts
• Reduced risk of incomplete syringe delivery

The regulatory pathway depends on the extent of the change. A formulation that remains qualitatively and quantitatively equivalent may fit an ANDA strategy. A materially different vehicle, concentration, or delivery system may require a 505(b)(2) application rather than a conventional ANDA.

2. Reduced-volume presentations

The 500 mg monthly dose requires two 5 mL injections. A 10 mL single-injection presentation would reduce injection count but could create practical limitations related to intramuscular tissue volume, syringe dimensions, injection force, and local tolerability.

A more commercially realistic approach is a higher-concentration formulation that delivers 500 mg in two smaller-volume syringes. Such a product could improve administration without requiring a single 10 mL injection.

Key development variables include:

• Maximum acceptable gluteal injection volume
• Fulvestrant solubility at higher concentration
• Viscosity at administration temperature
• Precipitation after injection
• Injection-site tolerability
• Dose uniformity across the syringe fill volume

3. Benzyl-alcohol reduction or replacement

Benzyl alcohol is a recognizable formulation target because of its toxicological profile in vulnerable populations and its role in local tolerability. A benzyl-alcohol-free formulation could create differentiation, although the excipient also contributes to solvent performance.

Potential replacement strategies include:

• Adjusting the benzyl benzoate-to-castor-oil ratio
• Using alternative pharmaceutically accepted cosolvents
• Applying a different oil phase
• Developing a nonaqueous preservative-free single-dose presentation
• Using container-closure sterilization and aseptic filling controls to eliminate preservative dependence

Each approach requires a new assessment of solubility, degradation products, extractables, leachables, microbial controls, and local tissue response.

4. Alternative oil vehicles

Alternative oils, including synthetic or semisynthetic lipid vehicles, may provide a path to lower viscosity or improved injection performance. Candidate vehicles must have established parenteral-use histories and support a robust safety package.

The principal barriers are:

• Fulvestrant solubility
• Oxidative stability
• Peroxide formation
• Sterilization compatibility
• Syringe and stopper interaction
• Injection-site tolerability
• Batch-to-batch variability
• Regulatory acceptability of the new excipient combination

A vehicle change may produce a commercially superior product but can also move the program outside the simplest generic pathway.

What formulations are protected by Faslodex patents?

The original Faslodex patent estate covered fulvestrant chemistry, pharmaceutical compositions, and therapeutic uses. Those rights supported originator exclusivity during the early commercial period. The key commercial fact is that U.S. regulatory exclusivity for the original Faslodex product has ended, and generic fulvestrant products have entered the market.

The current U.S. competitive position is governed primarily by:

• FDA-approved generic products
• Reference-product labeling
• Manufacturing capability
• Supply reliability
• Hospital and specialty-pharmacy contracting
• Any later-issued formulation or device patents
• State and federal substitution rules

The original product’s excipient combination is not, by itself, a durable commercial moat once the relevant composition and use rights have expired. A new excipient system could create separate patentable subject matter if it demonstrates an unexpected stability, solubility, injection-force, tolerability, or pharmacokinetic advantage.

Patentability opportunities

A differentiated fulvestrant formulation may support claims directed to:

• Specific solvent ratios
• Narrow viscosity ranges
• Defined particle or precipitation profiles
• High-concentration fulvestrant solutions
• Benzyl-alcohol-free compositions
• Reduced injection-volume products
• Prefilled syringes with defined needle and stopper materials
• Depot formulations with controlled release
• Manufacturing methods that prevent crystallization
• Storage conditions that extend shelf life

Patent strength will depend on whether the claimed parameters are technically meaningful and non-obvious. Claims that merely substitute one routine pharmaceutical excipient for another are more vulnerable than claims tied to a demonstrated performance result.

When does Faslodex lose exclusivity?

Faslodex lost its practical market exclusivity after expiration of its principal U.S. patent and regulatory exclusivity periods. Fulvestrant is a small-molecule drug, so it is subject to the ANDA generic pathway rather than the biosimilar pathway.

Exclusivity factor	Faslodex status
New chemical entity exclusivity	Expired
Generic pathway	ANDA
Biosimilar pathway	Not applicable
Reference product	Faslodex
Current commercial focus	Generic price, supply, and formulation differentiation
Originator moat	Brand recognition, established supply, clinical familiarity, and device execution

The FDA Orange Book remains the controlling source for current patent and exclusivity listings. [3] Patent status can differ by jurisdiction, and foreign rights may have expired on a different schedule from U.S. rights.

What is the Orange Book status of Faslodex?

Faslodex is an FDA-listed reference drug for fulvestrant injection. The Orange Book provides the relevant information for therapeutic-equivalence evaluations, patents, and exclusivity. With the original exclusivity period completed, generic manufacturers can compete through approved ANDA products subject to applicable patent certifications and labeling restrictions. [3]

An ANDA applicant may certify that listed patents are expired, will expire on a stated date, are not infringed, or are invalid. A Paragraph IV certification can trigger patent litigation if the brand holder files suit within the statutory period. That litigation may delay approval or market entry under the Hatch-Waxman framework. [4]

Which companies are challenging or competing with Faslodex?

Competition comes from generic injectable manufacturers rather than biosimilar developers. The competitive field includes companies with sterile fill-finish capacity, access to the required oil-based excipients, and the ability to supply oncology distributors and hospital systems.

The primary competitive groups are:

1. Established generic manufacturers with approved fulvestrant injections.
2. Contract development and manufacturing organizations with nonaqueous sterile-fill capability.
3. Specialty injectable companies pursuing formulation or device improvements.
4. Originator-linked suppliers protecting Faslodex availability and commercial positioning.

Fulvestrant is more operationally demanding than a conventional aqueous vial. The product requires control of viscous, flammable or volatile solvent components, syringe filling, particulate limits, container-closure integrity, and injection performance. These requirements reduce the number of manufacturers that can reliably scale the product.

What generic entry risks exist for Faslodex?

Generic entry has already reduced the protection provided by the Faslodex brand. The remaining commercial risks are concentrated in price erosion, supply disruption, formulation substitution, and potential clinical preference for newer endocrine therapies.

Price erosion

Fulvestrant generics are exposed to payer and hospital purchasing pressure. Multiple approved suppliers can produce substantial price compression. A manufacturer with only a conventional formulation has limited protection against this outcome.

Supply risk

Sterile injectable shortages can create temporary opportunities for manufacturers with validated capacity. Fulvestrant supply depends on specialized raw materials, reliable syringe components, and controlled filling of a viscous formulation. A second-source strategy can command value even when the product itself is no longer patent-protected.

Substitution risk

Newer oral endocrine therapies, CDK4/6 inhibitor combinations, and oral selective estrogen receptor degraders can reduce demand for intramuscular fulvestrant in some treatment settings. The commercial position of fulvestrant depends on clinical sequencing, biomarker status, tolerability, access, and physician preference.

How strong is the Faslodex patent estate?

The original Faslodex estate was commercially important but is no longer a broad barrier to ordinary generic entry. Its residual strength depends on later patents covering specific formulations, devices, manufacturing processes, or treatment combinations.

A practical strength assessment is:

Patent category	Current strategic value
Core fulvestrant composition	Low after expiration
Original injectable formulation	Low for ordinary generic entry after expiration
Method-of-use claims	Limited where expired or carved out
New excipient combinations	Potentially moderate to strong if technically differentiated
Prefilled syringe or injection device	Potentially moderate
Manufacturing process	Moderate if difficult to design around
Combination therapy claims	Relevant to treatment strategy, not basic generic injection supply

A new entrant should separate freedom-to-operate analysis for the active ingredient, vehicle, syringe, stopper, needle, manufacturing process, and label.

What FDA regulatory pathway applies to a new Faslodex formulation?

A conventional generic product normally uses the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to Faslodex. A materially different formulation may require a 505(b)(2) application.

ANDA strategy

An ANDA candidate generally seeks to match the reference product in:

• Active ingredient
• Strength
• Dosage form
• Route of administration
• Pharmaceutical equivalence
• Bioequivalence
• Labeling, subject to permitted differences
• Quality and manufacturing standards

The closer the excipient system remains to the reference formulation, the more straightforward the regulatory strategy generally becomes.

505(b)(2) strategy

A 505(b)(2) program may be appropriate for:

• A new excipient system
• A higher-concentration formulation
• A reduced-volume injection
• A new delivery device
• A modified release profile
• A formulation with a different administration procedure

The sponsor must establish that the new product has an acceptable benefit-risk profile and provide bridging evidence to the existing fulvestrant data. [5]

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barrier is sterile processing of a high-viscosity, nonaqueous formulation. The process must control:

• Excipient water content
• Solvent evaporation
• Mixing uniformity
• Drug dissolution
• Temperature exposure
• Fill-volume accuracy
• Particulate contamination
• Syringe lubrication
• Stopper compatibility
• Container-closure integrity

Castor oil and benzyl benzoate can interact with elastomers, lubricants, adhesives, and syringe materials. Extractables and leachables testing is therefore central to a commercially credible product.

The most defensible intellectual-property position will usually combine formulation claims with device and process claims. A formulation-only patent may be easier to design around through changes in excipient ratios. A process patent may have more practical value if the manufacturing method is difficult to replicate and produces a measurable quality advantage.

What licensing deals could create value?

Licensing opportunities are most likely in four areas:

• A validated low-viscosity fulvestrant vehicle
• A higher-concentration, reduced-volume formulation
• A prefilled syringe or autoinjector platform
• A sterile manufacturing process for nonaqueous oncology injectables

An excipient supplier could license a proprietary parenteral solvent system to a generic manufacturer. A device company could partner with a formulation sponsor to integrate a low-force syringe. A contract manufacturer could offer a complete development package covering formulation, analytical methods, fill-finish, and regulatory support.

The strongest deal structure would link the excipient or device to measurable commercial outcomes, such as reduced injection time, lower injection force, longer shelf life, fewer injections, or reduced manufacturing loss.

How does Faslodex compare with emerging oral estrogen receptor degraders?

Faslodex has an administration advantage for patients who benefit from injectable therapy and an administration disadvantage because of the two-injection monthly regimen. Oral estrogen receptor degraders can improve convenience but introduce adherence, absorption, drug-interaction, and gastrointestinal considerations.

Commercial factor	Faslodex	Oral estrogen receptor degrader
Administration	Intramuscular	Oral
Adherence control	Administered by healthcare professional	Patient-dependent
Excipient opportunity	Vehicle, syringe, injection volume	Tablet or capsule formulation
Generic pathway	ANDA	ANDA after applicable exclusivity
Device dependence	High	Low
Manufacturing complexity	Sterile nonaqueous injection	Solid oral manufacturing
Differentiation route	Lower viscosity, fewer injections, better device	Bioavailability, dosing, tolerability, convenience

Faslodex formulation innovation has value where clinicians prioritize administered dosing, where oral therapy is unsuitable, or where a lower-burden injection can preserve the clinical role of fulvestrant.

Key Takeaways

• Faslodex contains fulvestrant in a nonaqueous system of refined castor oil, benzyl benzoate, benzyl alcohol, and ethanol.
• The principal formulation challenge is balancing solubility against viscosity, injection force, and local tolerability.
• The strongest commercial opportunities are lower-viscosity vehicles, higher-concentration presentations, reduced injection volume, and improved prefilled syringes.
• Fulvestrant is a small molecule. Biosimilar competition does not apply; generic ANDA competition does.
• Original Faslodex exclusivity has ended, so ordinary vehicle replication has limited strategic value.
• A materially different formulation may require a 505(b)(2) application and can support new composition, device, or manufacturing patents.
• Sterile fill-finish capability, syringe compatibility, and supply reliability are major barriers to entry.
• Emerging oral estrogen receptor degraders create long-term demand risk for intramuscular fulvestrant.

FAQs About Faslodex Excipients and Commercial Strategy

Is Faslodex an aqueous or oil-based injection?

Faslodex is an oil-based, nonaqueous injectable solution. Refined castor oil is the principal vehicle.

Does Faslodex contain benzyl alcohol?

Yes. Faslodex contains benzyl alcohol, which functions as a cosolvent and preservative-related formulation component.

Can a generic manufacturer remove benzyl alcohol from fulvestrant injection?

Yes, but removing benzyl alcohol changes the formulation and may affect solubility, stability, sterility strategy, local tolerability, and regulatory pathway. The resulting product may require a 505(b)(2) approach.

Is there a biosimilar version of Faslodex?

No. Fulvestrant is a chemically synthesized small molecule, so competing products are regulated as generics or potentially as 505(b)(2) products, not biosimilars.

What is the most valuable formulation improvement for fulvestrant?

A higher-concentration, lower-viscosity formulation that reduces injection volume and administration force has the clearest commercial differentiation potential.

Sources

1. AstraZeneca Pharmaceuticals LP. (2024). Faslodex (fulvestrant) injection prescribing information. U.S. Food and Drug Administration.
2. National Library of Medicine. (2024). Faslodex-fulvestrant injection, solution. DailyMed.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2023). Abbreviated new drug application approvals and patent certifications. Center for Drug Evaluation and Research.
5. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). Center for Drug Evaluation and Research.